Is IL-1 a good therapeutic target in the treatment of arthritis?

D Burger, JM Dayer, G Palmer, C Gabay - Best practice & research Clinical …, 2006 - Elsevier
Inflammation is an important homeostatic mechanism that limits the effects of infectious
agents. However, inflammation might be self-damaging and therefore has to be tightly …

[HTML][HTML] Giant cell arteritis: 2018 review

A Winkler, D True - Missouri medicine, 2018 - ncbi.nlm.nih.gov
Giant cell arteritis is the most common large vessel vasculitis. Classic symptoms include
headaches, scalp tenderness, visual loss and muscle stiffness and pain. First line treatment …

[HTML][HTML] Characterization of the inflammatory cells in ascending thoracic aortic aneurysms in patients with Marfan syndrome, familial thoracic aortic aneurysms, and …

R He, DC Guo, W Sun, CL Papke, S Duraisamy… - The Journal of thoracic …, 2008 - Elsevier
OBJECTIVE: This study sought to characterize the inflammatory infiltrate in ascending
thoracic aortic aneurysm in patients with Marfan syndrome, familial thoracic aortic aneurysm …

Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein …

S Tsimikas, GW Duff, PB Berger, J Rogus… - Journal of the American …, 2014 - jacc.org
Objectives: The aim of this study was to assess the influence of pro-inflammatory interleukin
(IL)-1 genotype status on the risk for coronary artery disease (CAD), defined as> 50 …

Pathogenesis of giant cell arteritis: More than just an inflammatory condition?

KH Ly, A Régent, MC Tamby, L Mouthon - Autoimmunity reviews, 2010 - Elsevier
Giant cell arteritis (GCA) is characterized by intimal hyperplasia and luminal obstruction
leading to ischemic manifestations involving extra-cranial branches of carotid arteries and …

[HTML][HTML] Giant cell arteritis: current treatment and management

C Ponte, AF Rodrigues, L O'Neill… - World Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Glucocorticoids remain the cornerstone of medical therapy in giant cell arteritis (GCA) and
should be started immediately to prevent severe consequences of the disease, such as …

Interleukin-1 blockade in refractory giant cell arteritis

KH Ly, J Stirnemann, E Liozon, M Michel, O Fain… - Joint Bone Spine, 2014 - Elsevier
Giant cell arteritis is a primary large-vessel vasculitis characterized by an arterial wall
inflammation associated with intimal hyperplasia leading to arterial occlusion …

Interleukin 1 receptor antagonist deficiency presenting as infantile pustulosis mimicking infantile pustular psoriasis

K Minkis, I Aksentijevich… - Archives of …, 2012 - jamanetwork.com
Background Deficiency of interleukin 1 receptor antagonist (DIRA) is a recently described
autoinflammatory syndrome of skin and bone caused by recessive mutations in the gene …

Biological treatments in giant cell arteritis & Takayasu arteritis

M Samson, G Espígol-Frigolé… - European journal of …, 2018 - Elsevier
Giant cell arteritis (GCA) and Takayasu arteritis (TAK) are the two main large vessel
vasculitides. They share some similarities regarding their clinical, radiological and …

Vasculitis and vasculitis-like manifestations in monogenic autoinflammatory syndromes

A Jain, DP Misra, A Sharma, A Wakhlu… - Rheumatology …, 2018 - Springer
Monogenic autoinflammatory syndromes are a rare group of disorders characterized by
periodic episodes of systemic inflammation of endogenous origin. Sometimes, these …